Using this GBM-on-a-chip model, a novel dual αvβ3 and TGF-β1 blockade was found to suppress tumor neovascularization of GBM by simultaneously targeting endothelial-macrophage interactions and macrophage-associated immunosuppression. Here, TGFB1 is linked to neoplasm.